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Overexpression or amplification of ACTR (also named AIB1, RAC3, p/CIP, TRAM-1, and SRC-3), a member
of the p160 family of coactivators for nuclear hormone receptors, has been frequently detected in multiple types
of human tumors, including breast cancer. However, its role in cancer cell proliferation and the underlying mech-
anism are unclear. Here, we show that overexpression of ACTR not only enhances estrogen-stimulated cell pro-
liferation but also, more strikingly, completely negates the cell cycle arrest effect by tamoxifen and pure anti-
estrogens. Unexpectedly, we found that ACTR directly interacts, through its N-terminal domain, with E2F1 and
is recruited to E2F target gene promoters. Elevation of ACTR in quiescent cells strongly stimulates the tran-
scription of a subset of E2F-responsive genes that are associated with the G1/S transition. We also demonstrat-
ed, by adenovirus vector-mediated RNA interference, that ACTR is required for E2F1-mediated gene expression
and the proliferation of estrogen receptor (ER)-negative breast cancer cells. Moreover, the ability of elevated
ACTR to promote estrogen-independent cell proliferation depends on the function of E2F1 and the association
between ACTR and E2F1, but not ER. Thus, our results reveal an essential role of ACTR in control of breast
cancer cell proliferation and implicate the ACTR-E2F1 pathway as a novel mechanism in antiestrogen resistance.
ACTR (also named AIB1, RAC3, and TRAM1; named
SRC-3 and p/CIP in the mouse) is a member of the p160/SRC
coactivator family (17, 20, 30, 32). Like other p160 coactiva-
tors, ACTR/AIB1 was identified as a nuclear cofactor that
associates with hormone-bound nuclear receptors and medi-
ates the transcriptional activation function of the receptors (2,
7, 25, 44, 45). Structural and functional studies revealed that
the p160s contain functional domains for histone acetyltrans-
ferase activity and interactions with ligand-bound receptors,
the coregulator proteins CBP and p300, PCAF, and arginine
methyltransferase CARM1. Evidence from biochemical stud-
ies suggests that the association with the above-mentioned
cofactors is important for the p160s to mediate the transacti-
vation by nuclear receptors (15, 42). It is generally conceived
that the p160s are recruited to hormone-responsive genes
through their interaction with activated receptors and then
nucleate the assembly of a coactivator complex, which in turn
remodels chromatin through histone modifications and facili-
tates RNA polymerase II transcription. The role of ACTR/AIB1
as well as the other p160s in animal development and physi-
ology has been explored by genetic approaches (18, 35, 51, 56,
57). Similar to the other p160 knockouts, p/CIP/SRC-3 knock-
out mice exhibited abnormal development and reduced func-
tion of their reproductive systems. Unlike the SRC-1 knockout
mice, however, animals with the SRC-3/p/CIP gene deleted
displayed significant somatic growth retardation and a reduced
capacity of growth factor-stimulated cell proliferation, al-
though the underlying molecular mechanism is unclear (51, 56).
The growth of estrogen receptor (ER)-positive human breast
cancers is generally dependent on stimulation by estrogens (1).
Experimental evidence indicates that ER mediates the mito-
genic effect of estrogen primarily by up-regulating transcrip-
tion of cyclin D1 (37, 41). Hyperphosphorylation of pRb by
increased cyclin D1-Cdk activities leads to accelerated G1 pro-
gression. Antiestrogens such as tamoxifen are effective in an-
tagonizing the growth of ER-positive breast cancer by arresting
cells in G0/G1. However, resistance to such endocrine therapy
often evolves after prolonged treatment. Several potential mech-
anisms have been proposed to account for the development of
antiestrogen resistance (1). Overexpression of ERBB2 and/or de-
regulation of other kinase-mediated signaling could allow ER to
be phosphorylated and activated independent of hormones,
which could enhance ER’s ability to interact with the coactivators
and activate transcription. Down-regulation of transcriptional
corepressors may inhibit the transcriptional repression activity of
antiestrogen-bound ER. These molecular events would culminate
in increased expression and activity of cyclin D1-Cdks. On the
other hand, subgroups of ER-positive and -negative breast can-
cers do not contain high levels of cyclin D1; instead, they overex-
press cyclin E (22, 26), suggesting that alternative mechanisms
contribute to cell cycle progression in breast cancer.
The identification of ACTR/AIB1 as a gene amplified (in
less than 10%) and/or overexpressed in over 30% of breast
cancers provided the first genetic link of aberrant ACTR/AIB1
function to tumorigenesis (2). The fact that ACTR/AIB1 is a
coactivator for nuclear receptors, including ER, and the initial
analysis showing a correlation between ACTR/AIB1 amplifi-
cation and positive ER status in breast cancers support the
assertion that deregulated ACTR/AIB1 accelerates breast can-
cer cell proliferation by amplifying the mitogenic effect of
estrogen through potentiating the transactivation activity of
ER. However, subsequent studies with unselected breast can-
cer samples found that overexpression of ACTR/AIB1 does
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not correlate with ER status, but instead correlates with ab-
normal levels of HER-2/neu/ERBB2 (4). Further investiga-
tions found ACTR/AIB1 amplification and/or overexpression
in other malignancies, including gastric, pancreatic, and hepa-
tocellular carcinomas (19, 39, 50). It is likely that aberrant
ACTR/AIB1 function in cancer may target other nuclear re-
ceptors and/or cellular factors, in addition to ER.
We report here that ACTR is required for both estrogen-
stimulated and ER-independent breast cancer cell prolifera-
tion and that ACTR overexpression renders ER-positive cells
completely resistant to antiestrogens. We provide several lines
of evidence that ACTR can function as a coactivator for one of
the key cell cycle regulators, E2F1, which underlies the change
of gene expression and cell proliferation we observed in breast
cancer cells with ACTR overexpression. Therefore, our results
suggest a novel mode of ACTR/AIB1 function in breast cancer
and directly link ACTR/AIB1 to cell cycle control mechanisms.
MATERIALS AND METHODS
RNAi adenovirus vectors and adenovirus vectors for gene expression. For
RNA interference (RNAi) vector construction, the human H1 gene promoter
sequence was inserted into the pShuttle plasmid from the Adeasy system (21).
Oligodeoxynucleotides containing coding sequences for small interfering RNA
(siRNA) were inserted downstream of the H1 promoter (5). For ACTR expres-
sion, the original pShuttle-CMV was modified for improved expression. ACTR
cDNAs were inserted into the modified vector as described before (27). The
resulting pShuttle constructs were used to generate recombinant adenoviruses,
following the protocols described previously (21). Viruses were purified by cen-
trifugation in a CsCl step gradient. Viral titers were determined using 293 cells
by end point cytopathic effect assay with adeno-GFP as reference.
Cell cultures, stable transfectants, and reporter gene assay. All cells were
obtained from the American Type Culture Collection and maintained in the
recommended media with necessary supplements (Gibco). For generation of
sublines of T-47D cells ectopically expressing ACTR, T-47D cells were trans-
fected with pcD-HCMV-ACTR-HA and pcD-HCMV empty vector using Fu-
gene (Roche). Transfected cells were selected in medium containing G418 (700
g/ml). Individual clones were analyzed for ectopic ACTR expression using
antihemagglutinin (-HA; F-7; Santa Cruz) and ACTR (Transduction Labs)
antibodies. Reporter gene assays with promoter-luc were performed by trans-
fecting T-47D cells with firefly luciferase reporter plasmids pGL3-Cdk2 pro-
moter (3.5 kb) or cyclin E promoter (1.2 kb), pRL-SV40 Renilla luciferase
plasmid (Promega), and pcD-HCMV-ACTR-HA and pCMV-E2F1. Assays with
3x E2F-tk-luc and 3x ERE-tk-luc were performed by cotransfection in 293T cells
with pCMV-E2F1 and pSh-HCMV-ACTR-HA or its mutant forms using Lipo-
fectamine. Assays with pSh-Ri-ACTR, pSh-Ri-ERa, or pSh-Ri-GFP were per-
formed by cotransfection with 3x E2F-tk-luc and pCMV-E2F1. Forty-eight hours
after transfection, cells were harvested for Western and luciferase assays using a
dual luciferase assay kit (Promega). All reporter gene assays were performed in
triplicate, with the entire experiment repeated at least twice.
Cell proliferation and fluorescence-activated cell sorter (FACS) analysis of
cell cycle. T-47D and MDA-MB 361 cells were deprived of hormone by main-
taining them in medium supplemented with 5% hormone-depleted fetal bovine
serum (FBS) for the indicated times before infection with the adenovirus vectors.
ER-negative cells were treated in the same manner as ER-positive ones, except
they were maintained in medium supplemented with 2% hormone-depleted FBS
during the proliferation assay. Cell proliferation was measured every 2 days by
either a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
colorimetric assay (Sigma) or by cell counting of coded samples in triplicate.
Proliferation assays in the presence of antagonists 4(OH)-tamoxifen (Sigma) and
ICI 182,780 (herein referred to as ICI; Tocris) were conducted in similar fashion,
except cells were hormone deprived for at least 24 h and then treated with 108
M antagonist for 36 h prior to infection with adenovirus vectors. Cells were refed
with fresh medium containing specified ligands every 2 days. For cell cycle
analysis by flow cytometry, cells were hormone deprived and treated with ICI for
36 h before infection with either adeno-ACTR or adeno-GFP. At different times
after infection, cells were labeled with 10 M 5-bromo-2-deoxyuridine (BrdU;
Roche). An additional 10 h later, cells were harvested by trypsinization and
washed twice with phosphate-buffered saline. Cells were fixed with chilled 70%
ethanol and permeabilized in 2 N HCl and 0.1% Triton X-100. Following neu-
tralization with 0.1 M sodium tetraborate (Sigma), cells were incubated with
fluorescein isothiocyanate-conjugated -BrdU antibody (Roche) for 30 min in
the presence of 0.1% bovine serum albumin and 0.5% Tween 20. Cells were
washed twice and resuspended in phosphate-buffered saline containing 5 g
of propidium iodide (Sigma)/ml. Flow cytometry analysis was performed on a
FACScan (Coulter). Data were collected from 20,000 cells per sample.
ChIP assays. Chromatin immunoprecipitation (ChIP) assays were performed
essentially as described previously (27) with the following modifications. T-47D
cells grown to 70% confluence were hormone deprived, treated with 108 M ICI,
and infected with adenovirus vectors as described above for flow cytometry
analysis. After the indicated times, cells were fixed in 1% formaldehyde for 8
min. Cells were then washed and collected for sonication. The crude chromatin
solution was diluted and incubated with specific antibodies overnight at 4°C.
PCR was performed using 5 l of purified ChIP DNA for 28 cycles with pro-
moter-specific primers. Primer sequences are listed in the Appendix.
Western blotting and quantitative RT-PCR analysis. Whole-cell lysates were
prepared from cells treated and harvested at the indicated times in buffer con-
taining 50 mM Tris-HCl (pH 7.6), 150 mM NaCl, 10% glycerol, 0.5% Triton
X-100, 1 mM phenylmethylsulfonyl fluoride, and 1 protease inhibitor cocktail.
Western blotting analysis of proteins separated by sodium dodecyl sulfate-poly-
acrylamide gel electrophoresis (SDS-PAGE) was performed using the following
specific antibodies: -ACTR, -TIF2, -cyclin A, -cyclin B, and -Cdk4 (Trans-
duction Labs); -Cdk2 (M2), -Cdc2 (17) -cyclin D1 (H295), -cyclin D2 (C17),
-cyclin E (HE12), -SRC-1 (M341), -p107 (C18), -p130 (C20), -p21 (M19),
-p27 (M197), -E2F1 (KH95), -E2F3 (C18), and -E2F4 (C20; Santa Cruz);
-E2F2 (BD), -Rb (IF8), and -ER (Ab-15; Neomarkers); and --actin (Sig-
ma). For quantitative reverse transcriptase PCR (RT-PCR) analysis of gene
expression, total RNA was isolated with TRIzol reagent. Three micrograms of
total RNA was used for a reverse transcription reaction with Moloney murine
leukemia virus RT and oligo(dT)18 primers; cDNAs were diluted 10-fold, and a
5-l dilution was used for the PCRs. Gene sequences were amplified in the pres-
ence of SYBR Green fluorophore and detected using the iCycler real-time PCR
equipment (Bio-Rad). Fluorescent values after each elongation step were col-
lected along with a melting curve analysis at the end of the PCR. Fold difference
(N) was calculated using the equation N  E(CT of ACTR)  (CT of GFP), between
cells infected with adeno-ACTR and adeno-GFP, or as N E(CT of E2)  (CT of ICI),
between cells treated with estrogen and ICI. E is the PCR efficiency of the
specific primer pair used and was determined by the standard curve [E 
10(1/slope of standard curve)]. CT is the threshold cycle, which is defined as the cycle
number at which the fluorescence signal generated by the PCR product is first
detected. The primer sequences are listed in the Appendix.
Coimmunoprecipitation and GST pull-down. For immunoprecipitation,
T-47D cells infected with either adeno-ACTR or adeno-GFP and 293T cells
transfected with the expression constructs were lysed in 150 mM NaCl, 0.5%
NP-40, 2 mM EDTA, 10% glycerol, and 50 mM Tris-HCl (pH 8.0). Cell lysates
were sonicated, and cell debris was removed by centrifugation. The lysates were
precleared by incubation with protein A- or G-Sepharose beads (Zymed) for 1 h
at 4°C and then immunoprecipitated with -E2F1 (KH95), -E2F4 (A-20; Santa
Cruz), -ACTR (8), or control -mouse immunoglobulin G (IgG) monoclonal
antibody, followed by incubation with protein A or G beads. After extensive
washing, the precipitates were analyzed by Western blotting with -ACTR
(Transduction Labs), -E2F1, or -Flag antibodies. For glutathione S-trans-
ferase (GST) pull-down, ACTR proteins either purified as described previously
(8) or produced in the presence of [35S]methionine were incubated with an equal
amount of bead-bound GST fusion proteins at 4°C for 30 min in a binding buffer
containing 20 mM HEPES (pH 7.9), 150 mM KCl, 1 mM EDTA, 4 mM MgCl2,
1 mM dithiothreitol, 0.02% NP-40, 10% glycerol, 0.5 mM phenylmethylsulfonyl
fluoride, and 2 mg of bovine serum albumin/ml. The beads were washed three
times with the binding buffer and resuspended in SDS-PAGE sample buffer.
ACTR proteins retained on the beads were separated by SDS-PAGE and visu-
alized by Western blotting or autoradiography.
RESULTS
ACTR is required for both E2-stimulated and E2/ER-inde-
pendent breast cancer cell growth. We first examined the role
of ACTR in the proliferation of estrogen-responsive breast
cancer cells. To this end, we constructed adenoviral vectors to
mediate the expression of siRNA for specific silencing of
ACTR expression. As shown in Fig. 1A, the ACTR protein
level in T-47D cells was dramatically reduced 2 days after the
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cells were treated with ACTR RNAi (Ai) adenovirus vector,
while no significant effect was observed with the green fluores-
cent protein (GFP) RNAi (Gi) vector. Importantly, the expres-
sion of other p160 coactivators SRC-1 and TIF2/GRIP, as well
as ER, was not significantly affected (compare Ai with Gi
lanes). To examine the effect of ACTR depletion on estrogen-
stimulated cell proliferation, we treated ACTR-depleted
T-47D cells with 108 M 17-estradiol (E2). The results in
Fig. 1B indicate that depletion of ACTR dramatically inhib-
ited E2-stimulated cell proliferation. This remarkable effect
prompted us to examine whether hormone-independent growth
was also affected by ACTR depletion. As expected, T-47D cells
proliferated slowly without hormone stimulation (Fig. 1C; note
that cell numbers were only doubled after 6 days). Strikingly, in
the same experiment as in Fig. 1B, depletion of ACTR further
reduced the slow growth rate of T-47D cells in the absence of
E2 (Fig. 1C). We also depleted ACTR in ER-negative cells.
Results in Fig. 1D demonstrate that high levels of ACTR are
critical for hormone-independent proliferation of BT-20 cells.
Taken together, these results revealed that, in addition to
mediating estrogen induction of cell proliferation, ACTR plays
an important role in breast cancer cell proliferation that is
independent of estrogen and ER.
Elevation of ACTR expression promotes hormone-indepen-
dent cell growth and overcomes antiestrogen-mediated cell
cycle arrest. To directly address the consequences of ACTR
overexpression on cell proliferation, we ectopically expressed
ACTR using adenovirus vectors in a number of human breast
cancer cells with low to moderate levels of endogenous ACTR
protein (Fig. 2A, panel a, and data not shown). The ectopic
expression of ACTR was controlled at levels comparable to
those in MCF-7 cells and tumors where ACTR is amplified and
overexpressed (34) and did not affect the expression of other
coactivators and ER (unpublished data). Cell proliferation was
measured by MTT assay at different days after the viral vector
treatment. As expected, increased ACTR expression signifi-
cantly enhanced E2-stimulated cell proliferation (Fig. 2B, com-
pare ACTRE2 and GFPE2). Remarkably, overexpression
of ACTR increased hormone-independent cell proliferation to
a rate that was equivalent to E2-stimulated proliferation (com-
pare ACTR-E2 and GFPE2). Antiestrogens such as ICI ef-
fectively inhibit E2-stimulated cell proliferation by disruption
of ER-coactivator interactions and induction of ER proteolysis
(10, 12, 47, 53). Strikingly, when T-47D cells were rendered
quiescent by treatment with 4(OH)-tamoxifen or the pure an-
tiestrogen ICI, elevation of ACTR effectively promoted their
FIG. 1. Depletion of ACTR by adenovirus-mediated RNAi inhibits the proliferation of both ER-positive and -negative breast cancer cells. Cells
growing in six-well plates were hormone deprived prior to infection with an equal amount of adeno-ACTR-RNAi (labeled ACTR-Ri or Ai) or
adeno-GFP-RNAi (labeled GFP-Ri or Gi) at an estimated multiplicity of infection of 50. Different days after infection, cells were harvested for
Western analysis (A) or cell proliferation assay (B to D). For estrogen (E2)-stimulated proliferation analyses (as in panel B), cells were treated
with 108 M 17-estradiol (E2) when infected. Cells were refed with fresh medium containing E2 every 2 days or harvested and counted in
triplicate. For hormone-independent cell proliferation, cells were maintained in hormone-deprived medium. Cells mock infected showed no
difference in cell growth from cells infected with adeno-GFP-Ri.
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proliferation, even in the continuous presence of the anties-
trogens (Fig. 2C and unpublished data). Similar activities of
elevated ACTR to stimulate hormone-independent cell prolif-
eration and/or overcome the growth suppression by antiestro-
gens were observed in other E2-responsive cells, such as MDA-
MB-361 (Fig. 2D) and ZR-75-1 (data not shown), or when cells
were treated with ICI in regular growth medium (Fig. 2E).
These effects are unlikely to be caused by the viral vectors,
since cells treated with a viral vector expressing GFP and cells
mock treated had no difference in proliferation (unpublished
data). Nevertheless, to completely rule out the possibility that
viral vector itself might contribute to the effect of ACTR on
cell growth, we generated several T-47D derivatives that
showed different levels of ectopic ACTR expression (Fig. 2A,
panel b, and unpublished data). Significantly, the elevated lev-
els of ACTR in these stable cell lines correlated well with their
activity to stimulate hormone-independent cell proliferation
(Fig. 2F) and their ability to overcome the growth suppressive
effect of antiestrogens ICI and 4(OH)-tamoxifen (Fig. 2G and
data not shown). These results strongly suggest that overex-
pression of ACTR not only facilitates estrogen-stimulated cell
proliferation but also, more significantly, promotes hormone-
independent cell proliferation and renders estrogen-responsive
breast cancer cells resistant to antiestrogens.
Given that elevation of ACTR overcomes the cell cycle
arrest effect of antiestrogens, we postulated that the mecha-
nism of ACTR promotion of cell proliferation may entail its
direct involvement in cell cycle progression. We thus examined
the effect of ACTR overexpression on cell cycle distributions.
As illustrated in Fig. 3A, T-47D cells were first hormone de-
prived, then treated with ICI and adenovirus vectors, and
pulse-labeled for 10 h with BrdU before they were harvested
for cell cycle analysis by FACS. In agreement with previous
reports that antiestrogens inhibit ER-positive cell growth by
causing cell cycle arrest (36, 52), we found that treating T-47D
FIG. 2. Overexpression of ACTR stimulates hormone-independent
cell proliferation and confers antiestrogen resistance. (A) Ectopic ex-
pression of ACTR in T-47D cells by the adenovirus vector (a) or by
stable transfection (b). ACTR protein levels in T-47D cells infected
with adeno-ACTR (labeled with an A) or adeno-GFP (labeled with a
G) or mock infected (Mock) at different days after infection (a), or
levels in ACTR stable transfectants of T-47D cells (A6, A8, and A41)
and an empty vector transfectant (labeled with a V) (b) were deter-
mined by Western analysis of whole-cell lysates from cells grown in
hormone-depleted medium. (B) T-47D cells were hormone deprived
for 60 h before infection by adenovirus vectors for ACTR or GFP with
expression at an estimated multiplicity of infection of 100 and treated
with 108 M E2 (E2) or the solvent (-E2). Different days after in-
fection, cell proliferation was measured by the colorimetric MTT assay
in six replicates. (C) T-47D cells were hormone deprived for 24 h and
treated with 108 M ICI for 36 h prior to adenovirus vector infection.
Cells were then maintained in medium supplemented with 108 M ICI.
Cell proliferation was monitored as described for panel B. (D)
MDA-MB 361 cells were treated and analyzed as for panels B (except
no E2) and C. (E) T-47D cells grown in regular medium (RPMI plus
10% FBS) were treated with 107 M ICI for 36 h prior to adenoviral
infection. Cell proliferation was measured as described in the legend
for panel B. (F and G) The same number of T-47D stable transfectant
cells was plated. Different days after plating, cell proliferation was
measured by cell enumeration in triplicates in the absence of hormone
(F) or in the presence of 108 M ICI (G).
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cells with ICI inhibited S-phase entry by arresting cells primar-
ily in G1 (Fig. 3B, ICI only). Expression of GFP did not change
their cell cycle distribution. In contrast, 48 to 58 h after ACTR
adeno-vector treatment, a marked increase of cell population
in S phase was observed (from 8.6% in Ad-GFP to 27.5% in
Ad-ACTR [Fig. 3B]). Concomitantly, the number of cells in G1
decreased (from 80.7 to 66.0%). Significantly, the number of
BrdU-positive cells among ACTR-overexpressing cells was even
higher than that in cells treated with E2 (27.5 versus 22.6%), in
keeping with the strong effect of elevated ACTR on cell pro-
liferation. These results indicate that elevated levels of ACTR
in ER-positive breast cancer cells overcome the antiestrogen-
mediated growth arrest by induction of cell cycle reentry.
Elevated ACTR executes a gene expression program distinct
from that of E2-ER by selective induction of E2F target genes.
Because ACTR functions as a transcription cofactor, we rea-
soned that the effect of ACTR on cell cycle progression might
be due to its ability to modulate the expression of cell cycle
regulatory genes. In order to identify gene expressions directly
affected by elevated levels of ACTR, we first rendered T-47D
cells quiescent with ICI and then treated them with adeno-
vectors as illustrated in Fig. 3A. For comparison, we also in-
cluded cells treated with E2 or ICI. We first performed West-
ern analysis of the key cell cycle regulatory proteins (Fig. 4A).
Significant levels of ectopic ACTR expression could be de-
tected 24 h after adeno-vector treatment. In accordance with
previous findings, ICI treatment dramatically reduced the ex-
pression of ER in T-47D cells, which could be restored by E2.
Ectopic expression of ACTR or GFP, however, did not restore
the expression of ER, indicating that ACTR-stimulated cell
proliferation is not due to an up-regulation of ER expression.
Importantly, the expressions of E2F1, E2F3, cyclin E, cyclin A,
and Cdk2 were markedly increased within 36 h after ACTR
adeno-vector treatment. Notably, the increased expression of
E2F1 could be readily detected at 24 h, thus closely correlating
with the ectopic expression of ACTR. Furthermore, a repro-
ducible but less dramatic increase was also seen with cyclin B
and the Rb-related protein p107. Interestingly, while E2
strongly stimulated cyclin D1 expression, it did not markedly
affect E2F1 expression, as seen with ACTR. On the contrary,
overexpression of ACTR did not have any effect on the ex-
pression of cyclin D1. (Fig. 4A and unpublished data). Finally,
overexpression of ACTR appeared not to affect the expression
of p53, Erb2, and Akt (data not shown). These results suggest
that, in ER-positive cells, elevated levels of ACTR induce the
expression of key cell cycle regulators that are different from
those induced by E2.
To determine whether the detected changes occur at the
mRNA level, we performed quantitative analysis of gene tran-
scripts in cells treated with ICI and adenovirus vectors, as in
Fig. 4A. Indeed, the increase of E2F1, cyclin E, Cdk2, and
cyclin A proteins in cells with ACTR overexpression correlated
well with the increase of their RNA transcripts (Fig. 4B, panels
a to c, and data not shown). The apparent attenuation at 48 h
after adeno-vector treatment may reflect the fact that cells exit
G1 phase at that time point. Consistent with the Western
results, cyclin D1 transcription was strongly induced by E2, but
it was not influenced by the overexpression of ACTR (Fig. 4B,
panel d).
As essentially all of the genes with expression induced by
ACTR, including cyclin E, cyclin A, cyclin B, Cdk2, p107, and
E2F1 itself, are well characterized as targets of transcriptional
regulation by E2F1 (13, 33, 38, 48), we examined whether
other E2F1-responsive genes may also be subject to ACTR
regulation. Results in Fig. 4B, panels e to g, demonstrate that
Cdc25A, a cell cycle regulator, Cdc6, a component of DNA
replication machinery, and dihydrofolate reductase, an enzyme
involved in nucleotide biosynthesis, were all up-regulated by
elevated levels of ACTR. In contrast, the expression of other
E2F1 target genes, including Cdc2, Apaf1, and caspases 7, 8,
and 9, was not significantly altered in cells with a high level of
ACTR (panel h and data not shown). Taking together, these
results indicate that ACTR-induced promotion of cell cycle
progression correlates closely with its selective induction of
E2F1-responsive genes that are critical for G1/S transition.
ACTR is recruited to E2F1 target genes. Having demon-
strated that overexpression of ACTR enhances the expression
of a subset of E2F1-responsive genes, we asked if ACTR is
directly involved in E2F1-mediated control of their transcrip-
tion. Thus, we examined whether ACTR is recruited to the
target gene promoters by ChIP assay. Results in Fig. 5A show
that, in keeping with the E2-dependent role of ACTR in con-
trol of cyclin D1 expression, ectopically expressed ACTR, de-
tected by an -HA antibody, was recruited to the cyclin D1
promoter only in the presence of E2 (lane 5). In contrast, the
occupancy of ACTR at the E2F1 target gene promoters, in-
FIG. 3. Elevation of ACTR promotes cell cycle progression in an-
tiestrogen-treated quiescent cells. (A) Schematics of the time course
for treatment of T-47D cells for cell cycle analysis by FACS (see
Materials and Methods for details). (B) Two-dimensional FACS dis-
tribution of T-47D cells treated as above, grown in regular medium
(Regular), or hormone deprived for 60 h (HD), or treated with 107 M
E2 (E2 48 h), and then labeled with BrdU for 10 h prior to harvesting
and staining with propidium iodide. The horizontal axis in the dot plots
reflects DNA content, and the vertical axis shows DNA synthesis. The
populations of cells in G1 and S phases are indicated. Cells mock
infected showed no difference in cell cycle distribution from cells
infected with adeno-GFP (data not shown).
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cluding Cdk2, cyclin E, cyclin A, and E2F1 itself, was readily
detected both in the presence and absence of hormone. No
ChIP signals were observed in cells treated with GFP–adeno-
vector. To determine whether the endogenous ACTR occupies
E2F gene promoters, we performed a ChIP assay with an -
ACTR antibody. Indeed, a low amount of endogenous ACTR
was recruited to the E2F1 target gene independent of E2 (Fig.
5B, lanes 2 and 4). Ectopic expression of ACTR markedly in-
creased the overall ACTR occupancy (compare lanes 1, 3, and
5 with lanes 2 and 4). Importantly, promoter sequences from
genes that are not subject to ACTR regulation, such as caspase
9 and U6, were not detected in the immunoprecipitates (Fig.
5A and B), indicating that the observed ACTR chromatin
association is gene specific and not due to a nonspecific activity
of the antibodies used. These results provide a direct link of
ACTR to the transcriptional control of E2F1 target genes and
suggest that ACTR may act as a coactivator for E2F1.
ACTR, via one of its N-terminal domains, associates specif-
ically with E2F1. Although p160 coactivators, including ACTR,
were initially identified as nuclear hormone receptor cofactors
by virtue of their direct interactions with the receptors, recent
studies have begun to address the possible role of p160 coac-
tivators in other biological pathways mediated by nonreceptor
transcription factors (3, 9, 23, 24, 40, 54, 55). The direct in-
volvement of ACTR in regulation of E2F1-responsive genes
implies that ACTR may associate with E2F1. To test this, we
first performed coimmunoprecipitation assays to detect the
ACTR-E2F1 complex in T-47D cells. Cells were treated with
ICI and adeno-vectors as in the experiment shown in Fig. 3.
Cell lysates were incubated with -E2F1 or -IgG monoclonal
antibodies, and the presence of ACTR in immunoprecipitates
was analyzed by Western blotting with an -ACTR antibody.
Results in Fig. 6A show that a fraction of endogenous ACTR
was coprecipitated with E2F1 (top panel, lane 3) and that
elevation of the ACTR level increased the efficiency of ACTR-
E2F1 complex formation (lane 4). We also performed recip-
rocal coimmunoprecipitation assays with HEK-293T cells.
ACTR was expressed by transient transfection together with
E2F1 or Flag-E2F4. Protein complexes associated with -
ACTR antibody were then analyzed by Western blotting using
-E2F1 or -Flag antibodies. In line with the results using
-E2F1 antibody for coimmunoprecipitation, we found that
the -ACTR antibody effectively coimmunoprecipitated E2F1
(Fig. 6B, lane 3). Interestingly, ACTR appeared not to coim-
munoprecipitate with E2F4, the other member of the E2F
family (Fig. 6B, lanes 4 and 5).
Next, we examined whether ACTR directly interacts with
E2F1 by performing GST pull-down experiments using puri-
fied ACTR and GST-E2F proteins. Purified Flag-ACTR was
incubated with either GST, GST-E2F1, or GST-E2F4 immo-
bilized on glutathione beads. After extensive washing, proteins
retained on beads were separated by SDS-PAGE and detected
by Western analysis using the -Flag antibody. As demon-
strated in Fig. 6C, full-length ACTR interacted specifically
with E2F1, but not with E2F4 or GST alone. To examine the
FIG. 5. ACTR is selectively recruited to the promoters of cell cycle
genes. ChIP analysis of ACTR occupancy on E2F-responsive genes in
T-47D cells infected with adeno-ACTR-HA (labeled with an A) and
adeno-GFP (labeled with a G), or treated with 107M E2, after cells
were hormone deprived and treated with ICI. Cells were harvested 30
and 42 h after infection. The ChIP assay was performed using -HA
(A) or -ACTR (B) antibodies. (C) Fractions (5%) of total soluble
chromatin preparations made from cells treated for panels A and B
were taken before immunoprecipitation and used as input; the DNA
was isolated in the same way as for the ChIP assay. Usually 1/10 of the
DNA isolated from the input and the ChIP samples was used as
template for generation of the PCR products presented. Regions of
genomic sequence analyzed by PCR are indicated on the schematic of
each gene promoter.
FIG. 4. Overexpression of ACTR selectively induces the expression of E2F1-responsive genes, but not ER target genes. (A) The expression of
cell cycle regulatory proteins in T-47D cells was analyzed by Western blotting. Cells were treated with ICI and infected with adeno-ACTR (labeled
with an A) or adeno-GFP (labeled with a G) as described in the legend for Fig. 3A, and at different hours after infection cells were harvested for
Western blotting. Cells were refed every 2 days with fresh medium containing 108 M ICI. T-47D cells treated with 107 M E2 for 48 h or
continuously treated with ICI were included for comparison. (B, panels a to g) Quantitative RT-PCR analysis of E2F-responsive gene expression
in T-47D cells that were treated and/or infected with adeno-ACTR and adeno-GFP as described for panel A. Details of the procedures and
calculation of difference are described in Materials and Methods. (h) RT-PCR analysis (28 cycles at a Tm of 55°C) of E2F1 target genes that did
not show any significant changes of expression due to elevated levels of ACTR. E2F1 is shown for comparison.
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FIG. 6. ACTR interacts directly with E2F1 in vivo and in vitro through the N-terminal regions of ACTR and E2F1. (A) ACTR-E2F1 complex
in T-47D cells was analyzed by coimmunoprecipitation assay with cells treated with ICI and infected with adeno-ACTR (labeled with an A) or
adeno-GFP (labeled with a G). Two days after infection, cell lysates were prepared and immunoprecipitated with -E2F1 or -mouse IgG. The
presence of ACTR and E2F1 in the immunoprecipitates was detected by Western blotting using -ACTR and -E2F1 antibodies. Input was
equivalent to 20% of the cell lysate used in the IP. (B) 293T cells were cotransfected with expression plasmids for ACTR and E2F1 or Flag-E2F4
as indicated. Whole-cell lysates were immunoprecipitated with -ACTR or -E2F4, followed by Western analysis with -ACTR, -E2F1, or -Flag
5164 LOUIE ET AL. MOL. CELL. BIOL.
 o
n
 M
ay 31, 2016 by guest
http://m
cb.asm
.org/
D
ow
nloaded from
 
domains in ACTR that are required for its interaction with
E2F1, we performed similar experiments using in vitro-trans-
lated ACTR proteins. Results shown in Fig. 6D indicate that
the N terminus (amino acids [aa] 1 to 459) of ACTR interacted
strongly with E2F1, whereas the central and C-terminal re-
gions of ACTR, which are contained in the ACTR-A38 variant
with domains for interactions with nuclear receptors (RID),
CBP/p300 (CID), CARM1, and histone acetyltransferase ac-
tivity, did not show strong interactions with E2F1. Interest-
ingly, a C-terminal deletion of ACTR, leaving only the putative
bHLH and PAS domains (aa 1 to 343) intact, completely abol-
ished the interaction, suggesting that the region immediately
downstream of the PAS domains is critical for mediating
ACTR-E2F1 interaction. Consistent with this notion, a small
ACTR fragment of about 110 aa (aa 343 to 454) from a region
between the PAS and the RID domains displayed a strong
interaction with E2F1 (Fig. 6D, bottom portion), while an
internal deletion of the same region diminished the interaction
(Fig. 6E, bottom portion); we thus have named this region as
the E2F1 interaction domain, or EID. In contrast, fragments
(aa 264 to 329 and aa 395 to 621) either upstream or down-
stream of the EID showed no detectable activity to associate
with E2F1 (Fig. 6D). Furthermore, deletion of the bHLH
and/or the PAS domains in the full-length ACTR proteins or
the N terminus (aa 1 to 459) did not show any negative effect
on their interaction with E2F1 (Fig. 6E and F, right panels).
Domain mapping on E2F1 demonstrated that ACTR proteins
interacted primarily with the N-terminal region (aa 1 to 284) of
E2F1, which contains the N terminus and part of the DNA
binding and dimerization domains (Fig. 6F). Collectively, these
results suggest that ACTR interacts directly with the N-termi-
nal region of E2F1 through a previously undefined domain in
the N terminus of ACTR.
ACTR is required for transactivation by E2F1. To further
establish that ACTR functions as an E2F1 coactivator, we first
asked whether ACTR stimulates E2F1-responsive promoters
in reporter gene assays (Fig. 7A and B). T-47D cells were
transfected with the luciferase gene directly linked to cyclin
E or cdk2 promoter sequences. Expression of ACTR slightly
enhanced the reporter gene activity, presumably in part
through its interaction with the endogenous E2F1. Impor-
tantly, simultaneous expression of ACTR and E2F1 signifi-
cantly increased E2F1-mediated induction of the two promoter
activities. To rule out the possibility that ACTR targets tran-
scription factors other than E2F1 on the promoters, we carried
out the transfection assay with three E2F1 binding sites linked
to a tk-TATA-luciferase reporter. Similar to the effect ob-
served on the E2F1 target gene promoters, cotransfection of
ACTR markedly augmented E2F1-mediated transactivation
through the defined E2F1 sites (Fig. 7C). More importantly,
ACTR deletion mutants, such as ACTR	344-454, which spe-
cifically impairs its interaction with E2F1, displayed diminished
activities to stimulate E2F1 transactivation (Fig. 7D). In con-
trast, the same mutants possessed the full activity of wild-type
ACTR to potentiate ER-mediated induction of ERE-reporter
activity. They also showed equivalent expression levels in trans-
fected cells (data not shown). These results not only demon-
strate a direct enhancement of E2F1 transactivation by ACTR
but also reveal a structural requirement for ACTR to act as a
coactivator for E2F1, which is distinct from that for ER.
To more rigorously test the notion that ACTR can act as an
E2F1 coactivator, we examined the effect of ACTR depletion
on the transactivation activity of E2F1. As demonstrated in
Fig. 7E, cotransfection of an ACTR RNAi vector, Ri-ACTR1,
mediating the expression of siRNAs specifically against ACTR,
dramatically reduced E2F1 induction of reporter activity, while
no significant effect was observed with the ER and GFP-RNAi
vectors. Consistent with a weaker potency to silence ACTR ex-
pression (Fig. 7F), the other ACTR RNAi vector, Ri-ACTR8,
was less effective in suppression of E2F1 transactivation. These
results, together with the data described above, strongly suggest
that ACTR is indeed an E2F1 coactivator and is required for
E2F1-mediated transcriptional activation of gene expression.
ACTR-induced hormone-independent breast cancer cell
proliferation requires its association with E2F1 but not ER.
The results described above imply in many ways that induction
of E2F1-responsive gene expression and cell growth by ele-
vated ACTR may not involve ER. For instance, depletion of
ACTR in ER-negative cells decreases their hormone-indepen-
dent proliferation (Fig. 1). More strikingly, overexpression of
ACTR in ER-positive cells promotes cell cycle progression in
the presence of the pure ER antagonist ICI (Fig. 3). Anties-
trogens such as ICI not only decrease cellular ER protein
levels, they also effectively disrupt both hormone-dependent
and -independent interactions between ERs (both ER and )
and the p160 coactivators (10, 47), therefore making it unlikely
for ERs to contribute to the growth-promoting activity of
ACTR in the presence of antiestrogens. Nevertheless, to fur-
ther address the role of ACTR association with E2F1 and ER
in mediating E2-independent cell proliferation, we used sev-
eral mutant forms of ACTR that are selectively defective in
interactions with E2F1 and ER (Fig. 8A). The p160 coactiva-
tors interact with nuclear receptors primarily through the three
LXXLL motifs in their receptor interaction domain (20). The
ACTR-AAA mutant protein has the three LXXLL motifs
changed to LXXAA, which abolishes ACTR association with
the ER ligand-binding domain (6, 8, 11, 28, 31). When ex-
pressed in T-47D cells, the ACTR-AAA protein showed a
strong growth-promoting activity, equivalent to that of ACTR
wild type, suggesting that the growth-promoting function of
antibodies. The input represents 20% of the cell lysates. (C) In vitro direct interaction between ACTR and E2F1 was analyzed by GST pull-down
assay using purified proteins. Purified Flag-ACTR proteins were incubated with either GST, GST-E2F1, or GST-E2F4 immobilized on glutathione
beads. After extensive washing, proteins retained on beads were separated by SDS-PAGE and detected by Western analysis using -Flag antibody.
Input represents 30% of Flag-ACTR used in the assay. (D and E) A GST pull-down assay was also performed with in vitro-translated and
35S-labeled full-length or fragments of ACTR proteins and GST or GST-E2F1. Labeled proteins retained on the beads after washing were analyzed
by SDS-PAGE and autoradiography, together with 10% of the translated products used in the incubation. Note that the Gal4 DNA-binding
domain was fused to small ACTR fragments to enhance their in vitro translation signals. (F) GST fusions of full-length and fragments of E2F1
were incubated with in vitro-translated N-terminal fragments of ACTR. The left panel shows Coomassie stain of GST and the GST-E2F proteins used.
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FIG. 7. ACTR enhances the transactivation by E2F1. (A and B) Activity of ACTR to enhance the E2F1-responsive promoter function was
measured in T-47D cells using human cyclin E and cdk2 promoters linked to the luciferase gene. Cells were transiently transfected with the
reporters and ACTR or E2F1 expression constructs as indicated. Induction represents the normalized luciferase activity in cells transfected with
ACTR and/or E2F1 expression plasmids divided by the activity in cells transfected with the reporter alone. (C) The ability of ACTR to enhance
E2F1 transactivation was analyzed using 3x E2F- tk-luc, a reporter with three E2F1 binding sites linked to luciferase gene. 293T cells were
transfected with the reporter and plasmids expressing ACTR and/or E2F1. (D) The activity of wild-type and mutant ACTR to enhance E2F1
transactivation was compared with their activity on E2-stimulated ER transactivation. 293T cells were transfected with either 3x E2F-tk-luc or 3x
ERE-tk-luc reporter, along with expression plasmids for E2F1 or ER, and wild-type ACTR or its mutant forms (N-terminal deletions 338-C and
421-C and an internal deletion, 	344-454). Percentage of wild-type ACTR activity was calculated by dividing the normalized luciferase activity of
mutant ACTR with the normalized wild-type ACTR activity. The ERE reporter was analyzed from cells treated with 107 M E2. Note that ACTR
(wild type) increased E2-stimulated transactivation by ER about fourfold. (E) The requirement for ACTR in E2F1 transactivation was examined
in a reporter assay as for panel C, with ACTR expression silenced by vector-mediated RNAi. 293T cells were cotransfected with 3x E2F-tk-luc and
an equal amount of vectors expressing sh-RNAi sequences targeting ACTR, ER, or GFP as indicated. (F) 293T cells were cotransfected with
pcD-HCMV-ACTR and the pSh-RNAi vectors as indicated. Cell lysates were prepared 3 days after transfection for Western analysis.
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FIG. 8. Stimulation of hormone-independent cell proliferation by ACTR requires ACTR interaction with E2F1, but not ER. (A and B) T-47D
cells were infected with adenovirus expressing wild-type and mutant forms of ACTR, as depicted. The expression levels of different ACTR proteins
in the cells 2 days after infection were determined by Western blotting using -HA antibody. Cell proliferation in the absence of hormone was
monitored by MTT assay 4 days after infection as described in the legend for Fig. 2B, and the percentage of wild-type ACTR activity was
determined by dividing the proliferation induced by the mutant ACTR with that of wild-type ACTR. (C and D) ER-negative cells (HCC-1806 and
HCC-1937) infected with adeno-ACTR or adeno-GFP were monitored for cell proliferation by MTT assay. (E) T-47D and its derivative, A41 cells,
hormone deprived for 2 days, were infected with an equal titer of the RNAi adenoviruses for E2F1 or GFP, as for Fig. 1A. Cells were then
replenished with hormone-depleted medium either with (T-47D) or without (A41) 107 M E2. Cell proliferation was determined at 6 days after
infection, with the values from Ri-GFP adenovirus-infected cells set as 100 arbitrarily. Cells were also collected at day 6 postinfection for Western
analysis using -E2F1 and --actin. Note that no significant effect of GFP-RNAi vector on cell proliferation was observed when compared to
mock infection. (F) Potential pathways for elevated levels of ACTR to stimulate breast cancer cell proliferation.
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ACTR is not due to an enhanced association between ACTR
and the ligand-binding domain of ER. However, eliminating
the ACTR association with E2F1 by an N-terminal truncation,
as in ACTR-A38 (containing aa 421C), largely abolished the
function of ACTR to promote hormone-independent pro-
liferation (Fig. 8B). In contrast, expression of other N-ter-
minal-truncated ACTRs (D98 and D338) that retain the
ACTR-E2F1 interaction domain (EID) induced a hormone-
independent cell proliferation with the same efficacy as the
wild-type ACTR. Importantly, all the ACTR variants were
expressed at a similar level as in the wild type (Fig. 8A) and
possessed the full activity of wild-type ACTR to function as a
nuclear receptor coactivator, as shown in Fig. 7D and the
previous study (7).
Finally, to further establish the role of E2F1 and ER in
ACTR-induced hormone-independent breast cancer cell pro-
liferation, we first overexpressed ACTR in a number of ER-
negative human breast cancer cell lines (HCC1806, HCC1937,
and BT-20) that do not express ERs or respond to estrogen for
growth (unpublished results). Results in Fig. 8C and D (and
data not shown) demonstrated that overexpression of ACTR
markedly accelerated the proliferation of these ER-negative
cells in the absence of hormone. We then examined the effect
of E2F1 depletion on the proliferation of T-47D cells, and our
newly established T-47D derivative A41, which ectopically ex-
presses ACTR, showed robust E2-independent proliferation
(Fig. 2A, panel b, and F) and an elevated level of E2F1 (Fig.
8E, compare lane 4 with lane 2). Both types of cells were treat-
ed with an equal titer of the E2F1 RNAi or the control GFP
RNAi adenovirus vectors. E2-stimulated proliferation of T-47D
cells, and hormone-independent proliferation of A41 cells as well
as their E2F1 protein levels were determined 6 days after the
RNAi vector treatment. As shown in Fig. 8E, lane 1, although
E2F1 expression was effectively silenced in E2-treated T-47D
cells, the effect on cell proliferation was modest (about 30% de-
crease when compared to the control cells), suggesting that
factors other than E2F1 play a major role in ER-mediated cell
proliferation. In contrast, a less-efficient knocking down of E2F1
in the ACTR-overexpressing A41 cells (compare E2F1 levels in
lane 3 with lane 1) resulted in a dramatic inhibition of hormone-
independent proliferation (about 80% decrease), indicating
that E2F1 is a key mediator of ACTR-induced cell prolifera-
tion in the absence of E2. The results above, together with our
findings described in Fig. 1 and 2, provide strong evidence that
the ability of ACTR to promote hormone-independent breast
cancer cell proliferation does not requires its association with
ER, but instead involves its interaction with E2F1.
DISCUSSION
Apart from its established role in mediating nuclear receptor
function in hormone signaling, the p160 coactivator ACTR/
AIB1 has been strongly implicated in cancer, due to the fre-
quent detection of its amplification or overexpression in sev-
eral types of human tumors, particularly breast cancer. A pre-
sumed and not fully tested mechanism for the coactivator
action has been that elevated levels of ACTR/AIB1 promote
breast cancer cell proliferation through ER. Here, we provide
strong evidence that reveals an unexpected pathway for ACTR
to promote hormone-independent cell proliferation as well as
antiestrogen resistance.
To understand the role of ACTR/AIB1 in breast cancer, we
examined the function of ACTR/AIB1 in control of cell pro-
liferation and gene expression using a number of cell culture
models. In line with its role as a coactivator for ER, we found
that depletion of ACTR/AIB1 inhibited E2-stimulated cell
proliferation. Remarkably, however, we observed that overex-
pression of ACTR/AIB1 in ER-positive cells resulted in strong
enhancement of hormone-independent cell proliferation.
More strikingly, elevation of the coactivator expression com-
pletely negated the growth-suppressive effect of antiestrogens
ICI or tamoxifen and allowed the cells to proliferate robustly in
the presence of these antiestrogens. Furthermore, we found
that in ER-negative cells, depletion of ACTR/AIB1 suppressed
their proliferation, whereas its elevation elicited the opposite
effect. Unexpectedly, we found that ACTR/AIB1 can associate
with the key cell cycle regulatory protein E2F1, and elevated
levels of ACTR/AIB1 strongly stimulate the expression of pro-
growth E2F-responsive genes. Together, these results support
the hypothesis that ACTR/AIB1 plays an important role in
control of cell proliferation by both E2-ER-dependent and
-independent pathways and that the aberrant function of
ACTR/AIB1 in breast cancer, as a result of gene amplification
and/or overexpression, can bypass the E2-ER-dependent pro-
cess through its function as an E2F1 coactivator, therefore
helping tumor cells acquire antiestrogen resistance.
Based on previous findings and the results from this study,
we propose that ACTR/AIB1 can function in control of breast
cancer cell proliferation in at least three different modes. First,
ACTR/AIB1 can function primarily as a coactivator for E2-
bound ER, thereby mediating estrogen-dependent breast can-
cer cell growth (Fig. 8F, left side), which likely exists in the
majority of ER-positive primary breast cancers. Alternatively,
ACTR/AIB1 associates with ER independently of estrogen,
which is stimulated by growth factor-mediated phosphorylation
of ER and/or ACTR/AIB1 (16, 46). Conceivably, this latter
ACTR/AIB1 action mode can manifest itself in breast cancers
where HER2/neu and/or mitogen-activated protein kinase me-
diate sustained progrowth signaling. The third mode is the
aberrant function of ACTR/AIB1 to potentiate E2F-respon-
sive gene expression by acting as an E2F1 coactivator which, as
our results suggest, could operate in both ER-negative and
ER-positive breast cancers (Fig. 8F, right side). In support of
our prediction, recent studies revealed that overexpression of
ACTR/AIB1 in breast cancer did not correlate with positive
ER status (4). In fact, amplification and/or overexpression of
ACTR/AIB1 has been detected in a broad spectrum of malig-
nancies with high frequencies (19, 39, 50), where steroid hor-
mones such as estrogens are unlikely to play a critical role in
tumor growth. Therefore, our results and the findings from
clinical studies strongly support the notion that aberrant
ACTR may function in the regulatory circuitries of cell prolif-
eration that are independent of ER.
Distinct from the action of E2-ER, the ACTR-E2F1 mode
activates E2F1 itself, cyclin E, and the other E2F-responsive
genes, but not cyclin D1. Although overexpression of cyclin D1
is clearly linked to breast cancer, both E2F1 and cyclin E have
recently been recognized as potential proliferative markers of
the disease and closely correlated with poor outcomes (22, 26,
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58). Furthermore, overexpression of cyclin E in E2-responsive
cells could effectively overcome the growth arrest effect by
antiestrogens (14). Therefore, deregulated cyclin E and E2F1
functions could represent an important alternative mechanism
to derail the control of cell proliferation in breast cancer.
However, whether elevated levels and/or function of ACTR
triggers the alternative mechanism and leads to a hormone-
independent tumor growth is likely determined by cellular
context. Future studies aiming at defining the ACTR-E2F1-
cyclin E axis will help determine the significance of the ACTR-
E2F1 pathway in breast cancer progression.
The similarity of gene expression profiles generated by ele-
vated ACTR and E2F1 led to our investigation of whether
ACTR functions as an E2F1 coactivator. In this study, we
presented multiple lines of evidence to support our conclusion.
First, we found that ACTR is selectively recruited to the pro-
moters of E2F1 responsive genes that are activated by ACTR,
indicating a direct involvement of ACTR in transcriptional
control of a subset of E2F1 target genes. We then demon-
strated that ACTR interacts with E2F1 directly in vitro and in
vivo and that ACTR is required for E2F1-mediated transacti-
vation. Significantly, our domain mapping study localized the
E2F1 interaction to an N-terminal domain of ACTR that is
distinct from the receptor interaction domains. Moreover, we
found that loss of E2F1 interaction specifically abolishes the
ability of ACTR to enhance E2F1 transcription and promote
hormone-independent cell proliferation. Interestingly, several
nuclear proteins have recently been shown to interact with
different members of the p160s through their bHLH-PAS do-
mains and/or adjacent regions (3, 9, 55). Although our results
indicate that the bHLH-PAS domains are not required for ACTR
to promote cell proliferation, we cannot rule out that the N ter-
minus may play some regulatory role in this regard. Recently, we
found that the other p160 members SRC-1 and TIF2/GRIP1 may
also interact with E2F1 with varying strengths, and they share
some but not all the progrowth functions of ACTR we have ob-
served in both normal and malignant human cells (unpublished
data). These results, together with the report that overexpres-
sion of SRC-3/ACTR in a prostate cancer cell line affects
primarily cell growth (59), underscore the functional complex-
ity of the p160 gene family in control of cellular function.
In our attempt to explore the potential mechanism how
elevation of ACTR in quiescent cells activates E2F1-respon-
sive genes, we found that overexpression of ACTR altered the
promoter occupancies by different E2F family members (un-
published results). The E2Fs can be divided into subgroups with
opposing activities to control transcription of cell cycle genes
(48). In cells reentering the cell cycle by serum stimulation, de-
creased promoter occupancies of repressing E2Fs followed by
increased occupancies of activating E2Fs have been observed
(43). Serum stimulation is believed to cause hyperphosphory-
lation of Rb and related pocket proteins by Cdks, which in turn
results in the relocalization of freed repressive E2Fs to the
cytoplasm and subsequent recruitment of activating E2Fs. We
speculate that an increased expression of ACTR expands the
free pool of the activator ACTR-E2F complexes in quiescent
cells and enhances the potential of the complex to be recruited
to the E2F-responsive promoters, which in turn displaces the
repressive E2F complex. The ACTR-E2F complex could acti-
vate transcription through its associated chromatin-modifying
activities and the function to facilitate the recruitment of RNA
polymerase II-containing complexes, as recently demonstrated
(27). It is worth noting that CBP and PCAF were shown to
interact with E2F1 and modulate its transactivation (29, 49). It
would be of interest to determine how ACTR, p300/CBP, and
PCAF may relate to each other in control of the transcriptional
output of E2F transcription factors and cell proliferation.
APPENDIX
The primers listed in Table A1 were used in the quantitative RT-
PCR and the analysis of genomic DNA sequences enriched in the
ChIP.
TABLE A1. Primers used in this study
Primer Forward sequence Reverse sequence
RT-PCR primers
ACTR GATTAGGAGAAAACTTGGATCC TGTTTCCGTCTCGATTCACCA
Actin GAGAAAATCTGGCACCACACC ATACCCCTCGTAGATGGGCAC
Cyclin A CCCCCAGAAGTAGCAGAGTTTGTG GCTTTGTCCCGTGACTGTGTAGAG
Cyclin D1 TCCTGTGCTGCGAAGTGGAAAC AAATCGTGCGGGGTCATTGC
Cyclin E ATACAGACCCACAGAGACAG TGCCATCCACAGAAATACTT
Cdk2 TTTGCTGAGATGGTGACTCGC CACTGGAGGAGGGGTGAGATTAG
E2F1 CGCATCTATGACATCACCAACG GAAAGTTCTCCGAAGAGTCCACG
Cdc2 CCAAGTATTTCTTCAGATCCATGG GCACTTGGCTTCAAAGCTG
Cdc6 AAAGAGAATGGTCCCCCTCACTC AGTTTTTCCAGTTCCAGGAGCAC
Cdc25A TGAAGAATGAGGAGGAGACCCC CTGATGTTTCCCAGCAACTGTATG
DHFR CTTCCCAGATTCAAGCGATTCTC TCAAGCAACCATCATCCCTCAC
Apaf1 GTCATCATCTTCTCTTAGCCACTGG TTGCTGCCACCATTATCCTTG
Caspase 9 GGTTTTGTTTCCTGGAGGGACC TGCTAAGAGCCTGTCTGTCACTGG
ChlP primers
Cyclin A GAAAACGGAGAATCGGAGATACTG ACCCAAAGGAAACTGAGCAGGG
Cdk2 GATGGAACGCAGTATACCTCTC AAAGCAGGTACTTGGGAAGAGTG
CyclinE GCCGCCTGTCCATTCATCC GGTCCTGTGGAGCCTGTAGCC
E2F1 GCAAGTTGAGGATGGAAGAGGTG TGGGGACACGGGAACATAGG
Caspase 9 GCTCTTCCTTTGTTCATCTCCTGC ACGCCGCAACTTCTCACAGTC
U6 RNA GAGGGCCTATTTCCCATGATTC GAATTTGCGTGTCATCCTTGC
Cdc2 TGAGGTAGAAACAAAGCACAGCG TCCCAGCATTGGCACAGTTC
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